

# Resource Summary Report

Generated by RRID on May 23, 2025

## Hep-G2/C3A

RRID:CVCL\_1098

Type: Cell Line

### Proper Citation

(RRID:CVCL\_1098)

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_1098](https://web.expasy.org/cellosaurus/CVCL_1098)

**Proper Citation:** (RRID:CVCL\_1098)

**Sex:** Male

**Defining Citation:** [PMID:12068308](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#),  
[PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:29468137](#),  
[PMID:30894373](#), [PMID:31068700](#), [PMID:35839778](#)

**Comments:** Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Virology: Susceptible to infection by Zika virus (ZIKV) (PubMed=29468137)., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Patented cell line.

**Category:** Cancer cell line

**Name:** Hep-G2/C3A

**Synonyms:** HepG2/C3A, Hep G2/C3A, C3A

**Cross References:** BTO:BTO\_0003586, CLO:CLO\_0002119, EFO:EFO\_0002121, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-3610, ATCC:CRL-3581, ATCC:CRL-10741, BCRC:60177, BCRJ:0291, BioSample:SAMN03473207, BioSample:SAMN10987645, cancercelllines:CVCL\_1098, Cell\_Model\_Passport:SIDM01237, ChEMBL-Cells:CHEMBL3308377, ChEMBL-Targets:CHEMBL1075402, Cosmic:724820, Cosmic:910850, Cosmic:1995354, Cosmic-CLP:910850, DepMap:ACH-001021,

EGA:EGAS00001000610, EGA:EGAS00001000978, FCS-free:10-2-11-3-4-4, GDSC:910850, GEO:GSM886899, GEO:GSM887964, GEO:GSM1669638, IARC\_TP53:21205, IARC\_TP53:27688, IGRhCellID:C3A, LINCS\_LDP:LCL-1927, PharmacoDB:C3A\_156\_2019, PRIDE:PXD030304, Progenetix:CVCL\_1098, PubChem\_Cell\_line:CVCL\_1098, Ubigene:YC-C093, Wikidata:Q54882789

**ID:** CVCL\_1098

**Record Creation Time:** 20250131T200406+0000

**Record Last Update:** 20250131T201627+0000

---

## Ratings and Alerts

No rating or validation information has been found for Hep-G2/C3A.

No alerts have been found for Hep-G2/C3A.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 119 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#).

Bugide S, et al. (2024) ALK inhibitors suppress HCC and synergize with anti-PD-1 therapy and ABT-263 in preclinical models. iScience, 27(5), 109800.

Chen N, et al. (2023) Biocompatibility of the oxygen carrier polymerized human hemoglobin towards HepG2/C3A cells. Heliyon, 9(5), e15878.

N H, et al. (2023) In Vitro Hepatic Models to Assess Herb-Drug Interactions: Approaches and Challenges. Pharmaceuticals (Basel, Switzerland), 16(3).

Primadharsini PP, et al. (2023) Development and Characterization of Efficient Cell Culture Systems for Genotype 1 Hepatitis E Virus and Its Infectious cDNA Clone. Viruses, 15(4).

Nyambo K, et al. (2023) In-silico and in-vitro assessments of some fabaceae, rhamnaceae, apocynaceae, and anacardiaceae species against Mycobacterium tuberculosis H37Rv and triple-negative breast cancer cells. BMC complementary medicine and therapies, 23(1), 219.

Subramanian C, et al. (2023) Relief of CoA sequestration and restoration of mitochondrial function in a mouse model of propionic acidemia. *Journal of inherited metabolic disease*, 46(1), 28.

Schrader JA, et al. (2023) EGF receptor modulates HEV entry in human hepatocytes. *Hepatology* (Baltimore, Md.), 77(6), 2104.

Lin S, et al. (2023) Hepatitis E Virus: Isolation, Propagation, and Quantification. *Current protocols*, 3(1), e642.

Hsieh YY, et al. (2023) Repositioning VU-0365114 as a novel microtubule-destabilizing agent for treating cancer and overcoming drug resistance. *Molecular oncology*.

Meister TL, et al. (2022) A ribavirin-induced ORF2 single-nucleotide variant produces defective hepatitis E virus particles with immune decoy function. *Proceedings of the National Academy of Sciences of the United States of America*, 119(34), e2202653119.

Frandsen HS, et al. (2022) Mapping Proteome and Lipidome Changes in Early-Onset Non-Alcoholic Fatty Liver Disease Using Hepatic 3D Spheroids. *Cells*, 11(20).

Wang M, et al. (2022) Molecularly cleavable bioinks facilitate high-performance digital light processing-based bioprinting of functional volumetric soft tissues. *Nature communications*, 13(1), 3317.

Hernandez A, et al. (2022) Dihydroxyacetone suppresses mTOR nutrient signaling and induces mitochondrial stress in liver cells. *PLoS one*, 17(12), e0278516.

Gabuza KB, et al. (2022) In vitro and in vivo hepatotoxicity study of Afriflex™ GRT through an inflammatory response. *Toxicology reports*, 9, 1920.

Carabias P, et al. (2022) Galectin-1 confers resistance to doxorubicin in hepatocellular carcinoma cells through modulation of P-glycoprotein expression. *Cell death & disease*, 13(1), 79.

Burkard T, et al. (2022) Viral Interference of Hepatitis C and E Virus Replication in Novel Experimental Co-Infection Systems. *Cells*, 11(6).

Li H, et al. (2022) CRISPR/Cas9 Screens Reveal that Hexokinase 2 Enhances Cancer Stemness and Tumorigenicity by Activating the ACSL4-Fatty Acid ?-Oxidation Pathway. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 9(21), e2105126.

Ma Z, et al. (2022) Chronic hepatitis E: Advancing research and patient care. *Journal of hepatology*, 77(4), 1109.

Di Cristo L, et al. (2022) Grouping of orally ingested silica nanomaterials via use of an integrated approach to testing and assessment to streamline risk assessment. *Particle and fibre toxicology*, 19(1), 68.

Doß S, et al. (2022) Influence of Antibiotics on Functionality and Viability of Liver Cells In

